Poloxamer188 composite electrospun poly L-lactic acid fibrous nonwoven: Sustained in vitro and in vivo release letrozole as a subcutaneous implant

Author:

Wang Hao1ORCID,Huang Jiana1,Liu Yang2,Dong Xin1,Wen Meng1,Huang Jianhua3

Affiliation:

1. School of Pharmacy, Jinzhou Medical University, Jinzhou, China

2. Key Laboratory of Medical Macromolecule Materials of Shandong Province, Acadamy of Pharmaceutical Sciences Shandong Province, Jinan, China

3. The First Affiliated Hospital, Jinzhou Medical University, Jinzhou, China

Abstract

Poloxamer188 composite poly L-lactic acid (PLLA) electrospun fibrous nonwovens (EFNW) were prepared by simple letrozole-poloxamer188-PLLA co-solution electrospinning and used as subcutaneous implants to sustained release letrozole. Contents of poloxamer188 and letrozole were varied to investigate the effect of the two compounds’ amounts on drug release behavior. Materials’ combination and drug incorporation in fibers were investigated by X-ray diffraction and differential thermal calorimetry. Letrozole contents in vitro and in vivo were all determined by high-performance liquid chromatography-ultraviolet spectrometry. Meanwhile, in order to analyze the mechanism of drug release behavior and show modulated drug release by electrospun fibers, letrozole-poloxamer188 solid dispersions (SDs) and letrozole-poloxamer188poly L-lactic acid-dichloromethane solution cast films (CFs) were also studied. Plasma letrozole concentration curves of subcutaneous implanting EFNW and daily oral administration of poloxamer188-letrozole SD on female rabbits were investigated and compared. Fibers of desirable morphology were obtained. During the whole release process of all EFNWs, water-insoluble letrozole could be released in the form of being dissolved. Letrozole release rates increased with increasing poloxamer188 content and decreased with increasing letrozole content. When letrozole and poloxamer188 content in fibers was 30% and 150% (EFNW-30-150%), respectively (with respect to PLLA in mass ratio), the release curve presented a desirable profile. After subcutaneous implant of EFNW-30-150%, the plasma concentration curve presented a later peak time and lower maximum value, and a comparable bioavailability with daily oral administration of poloxamer188-letrozole SD solution within 15 days. The research provided primary and encouraging information to use EFNW as a novel subcutaneous implant for sustained delivery of water-insoluble drugs.

Publisher

SAGE Publications

Subject

Industrial and Manufacturing Engineering,Polymers and Plastics,Materials Science (miscellaneous),Chemical Engineering (miscellaneous)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3